By the end of this video, you will be able to describe safety
risks observed in three approved drugs. You will also be able to outline
the evolution of the regulatory approval process with respect
to preclinical safety. Sulfanilamide is an antibacterial
drug that is typically administered in pill form, pills can
be a challenge for small children. In 1937, a pharmaceutical company
created a new formulation for sulfanilamide, the new
formulation was a syrup. One of the solvents in the syrup
was diethylene glycol, or DEG, DEG imparted a sweet flavor to the syrup
to make it more palatable for children. The new formulation was marketed
as elixir sulfanilamide, the drug was distributed
in September 1937 and by October, patient deaths were reported. In total, over 100 deaths were linked
to DEG in elixir sulfanilamide, even at low doses,
DEG can cause kidney failure and death. At the time, preclinical safety
testing of new drugs and formulations was not required. Furthermore, the risks of DEG
were generally not known. Because of the elixir sulfanilamide
experience, the 1938 Food, Drug, and Cosmetic Act was
passed in the United States. The legislation gave the US Food and
Drug Administration authority to monitor the safety of drugs and
determine safety standards. Moving on to our next example. In 1957, the drug thalidomide
was marketed for anxiety and insomnia, the drug also reduced nausea and
was recommended for use in pregnant patients
experiencing morning sickness. In the following years, over 10,000
children were born with deformities associated with the use of
thalidomide by the pregnant mother. Thalidomide was subsequently removed
from markets, follow-up safety testing showed that thalidomide impairs organ and
tissue development in the fetus. The most commonly observed deformity
involves underdeveloped arms and or legs, a condition called phocomelia. The thalidomide tragedy affected children
in many countries around the world, the United States was
relatively unaffected. Largely because Francis Oldham Kelsey,
a reviewer for the US FDA, denied approval to thalidomide because of
unsatisfactory testing of the molecule. Learning from the thalidomide experience, most drug regulatory agencies around
the world increased requirements for preclinical safety testing
of new drug candidates. Interestingly, while thalidomide
has this very unfortunate history, it was later found to be useful for
treating certain types of cancer, as well as complications of leprosy. Our final example is terfenadine,
terfenadine is an antihistamine for the treatment of allergy symptoms. Within a few years of approval in
the mid 1980s, isolated patients taking terfenadine suffered arrhythmias,
which were often fatal. By 1990, the risks had been connected
to patients taking both terfenadine and either certain antibiotics or
antifungal agents. What was happening? To understand the toxicity of terfenadine, we need to look at
terfenadine more closely. Terfenadine, shown on the left, is a prodrug,
terfenadine is not active, but is metabolized by liver cytochrome P453A4 to a metabolite called fexofenadine. Fexofenadine is the active form of the
drug against the histamine H1 receptor. In most patients, conversion of
terfenadine to fexofenadine is fast. In rare cases, such as if a patient
is taking certain antibiotics or antifungal agents that
block the CYP3A4 enzyme, concentration of terfenadine will rise. Unknown at the time of
terfenadine's approval, terfenadine is a hERG channel blocker. HERG stands for
human ether-a-go-go receptor gene and encodes the pore-forming subunit of
the cardiac IKr potassium channel. Blocking the activity of
this cardiac ion channel can lead to life threatening arrhythmias. Based on the toxicity of terfenadine,
preclinical safety testing of molecules for hERG activity
has become standard practice. These three historical cases of
safety issues in approved drugs have yielded valuable insights and continue to affect preclinical
safety testing in today's new drugs.